Sandra Vukusic

List of Publications by Year
in descending order

68	11,005	159585 30	102487 66
papers	citations	h-index	g-index

69	69	69	9010
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, The, 2018, 17, 162-173.	10.2	4,605
2	Relapses and Progression of Disability in Multiple Sclerosis. New England Journal of Medicine, 2000, 343, 1430-1438.	27.0	1,135
3	Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain, 2003, 126, 770-782.	7.6	839
4	Natural history of multiple sclerosis: a unifying concept. Brain, 2006, 129, 606-616.	7.6	736
5	Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of postâ€partum relapse. Brain, 2004, 127, 1353-1360.	7.6	573
6	Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults. Neurology, 2018, 90, e1858-e1869.	1.1	401
7	Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis. JAMA Neurology, 2020, 77, 1079.	9.0	357
8	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
9	MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study. Multiple Sclerosis Journal, 2016, 22, 1719-1731.	3.0	249
10	Objective Evaluation of Multiple Sclerosis Lesion Segmentation using a Data Management and Processing Infrastructure. Scientific Reports, 2018, 8, 13650.	3.3	171
11	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibodyâ€“Associated Disease. Annals of Neurology, 2021, 89, 30-41.	5.3	123
12	MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.	3.6	119
13	Multiple sclerosis and pregnancy in the 'treatment era'. Nature Reviews Neurology, 2015, 11, 280-289.	10.1	99
14	Accumulation of irreversible disability in multiple sclerosis: From epidemiology to treatment. Clinical Neurology and Neurosurgery, 2006, 108, 327-332.	1.4	97
15	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1377-1384.	3.0	89
16	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
17	Comparative efficacy of fingolimod vs natalizumab. Neurology, 2016, 86, 771-778.	1.1	71
18	Observatoire FranÃ§ais de la SclÃ©rose en Plaques (OFSEP): A unique multimodal nationwide MS registry in France. Multiple Sclerosis Journal, 2020, 26, 118-122.	3.0	69

#	Article	IF	Citations
19	Cranial nerve involvement in patients with MOG antibodyâ€“associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.	6.0	53
20	Frequency of myelin oligodendrocyte glycoprotein antibody in multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	49
21	New OFSEP recommendations for MRI assessment of multiple sclerosis patients: Special consideration for gadolinium deposition and frequent acquisitions. Journal of Neuroradiology, 2020, 47, 250-258.	1.1	46
22	Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: Clinical study data and 5 years of post-marketing experience. Multiple Sclerosis Journal, 2020, 26, 829-836.	3.0	39
23	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. Multiple Sclerosis Journal, 2020, 26, 1031-1044.	3.0	39
24	Clinical spectrum of central nervous system myelin oligodendrocyte glycoprotein autoimmunity in adults. Current Opinion in Neurology, 2019, 32, 459-466.	3.6	38
25	Frequency and characteristics of short versus longitudinally extensive myelitis in adults with MOG antibodies: A retrospective multicentric study. Multiple Sclerosis Journal, 2020, 26, 936-944.	3.0	37
26	Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis. Neurology, 2019, 93, e635-e646.	1.1	36
27	Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France. JAMA Neurology, 2020, 77, 94.	9.0	36
28	Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 1001-1011.	10.2	36
29	Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 953-955.	3.0	35
30	Risk of relapse after natalizumab withdrawal. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e297.	6.0	34
31	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. Multiple Sclerosis Journal, 2021, 27, 1543-1555.	3.0	33
32	Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome. JAMA Network Open, 2021, 4, e2128271.	5.9	32
33	Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study. Journal of Neuroinflammation, 2022, 19, 62.	7.2	30
34	Peripheral small fiber dysfunction and neuropathic pain in patients with Morvan syndrome. Neurology, 2015, 85, 2076-2078.	1.1	28
35	Efficacy of rituximab in refractory RRMS. Multiple Sclerosis Journal, 2019, 25, 828-836.	3.0	28
36	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	7.6	24

#	Article	IF	Citations
37	Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. Journal of Neuroradiology, 2021, 48, 28-36.	1.1	24
38	Multiple sclerosis lesions segmentation from multiple experts: The MICCAI 2016 challenge dataset. NeuroImage, 2021, 244, 118589.	4.2	23
39	Multiple sclerosis broke my heart. Annals of Neurology, 2017, 81, 754-758.	5.3	22
40	Aggressive multiple sclerosis (2): Treatment. Multiple Sclerosis Journal, 2020, 26, 1045-1063.	3.0	21
41	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
42	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.1	15
43	Spontaneous multiple cervical artery dissections after alemtuzumab. Multiple Sclerosis Journal, 2020, 26, 381-383.	3.0	14
44	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Multiple Sclerosis Journal, 2019, 25, 591-600.	3.0	13
45	Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis optica. Multiple Sclerosis Journal, 2022, 28, 1155-1159.	3.0	13
46	Weekly enhanced T1-weighted MRI with Gadobutrol injections in MS patients: Is there a signal intensity increase in the dentate nucleus and the globus pallidus?. European Journal of Radiology, 2018, 105, 204-208.	2.6	12
47	Cumulative effects of therapies on disability in relapsing multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1760-1770.	3.0	11
48	Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort. Neurology, 2021, 97, e403-e413.	1.1	10
49	Pathologic and MRI analysis in acute atypical inflammatory demyelinating lesions. Journal of Neurology, 2019, 266, 1743-1755.	3.6	9
50	Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study. Multiple Sclerosis Journal, 2021, 27, 1458-1463.	3.0	8
51	Untreated patients with multiple sclerosis: A study of French expert centers. European Journal of Neurology, 2021, 28, 2026-2036.	3.3	8
52	Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. CNS Drugs, 2021, 35, 1217-1232.	5.9	8
53	MSCopilot: New smartphone-based digital biomarkers correlate with Expanded Disability Status Scale scores in people with Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2021, 55, 103164.	2.0	6
54	Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis. Neurotherapeutics, 2021, 18, 378-386.	4.4	5

#	Article	IF	Citations
55	Update on brain MRI for the diagnosis and follow-up of MS patients. Presse Medicale, 2021, 50, 104067.	1.9	5
56	Post-partum relapse in women with multiple sclerosis after neuraxial labour analgesia or neuraxial anaesthesia: A multicentre retrospective cohort study. Anaesthesia, Critical Care & Pain Medicine, 2021, 40, 100834.	1.4	5
57	Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsingâ€“Remitting Multiple Sclerosis After Fingolimod Withdrawal. Neurotherapeutics, 2022, 19, 476-490.	4.4	5
58	COPP-MS: COrticosteroids during the Post-Partum in relapsing Multiple Sclerosis patients. Journal of Neurology, 2022, 269, 5571-5581.	3.6	4
59	Clinical significance of a single cerebrospinal fluid immunoglobulin band: A retrospective study. Multiple Sclerosis Journal, 2020, 27, 135245852097822.	3.0	3
60	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	3.0	3
61	Signal Intensity Evaluation in the Dentate Nucleus and Subcortical Gray Matter. Clinical Neuroradiology, 2022, 32, 677-685.	1.9	3
62	Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. PLoS ONE, 2017, 12, e0185104.	2.5	2
63	Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk. Annals of Neurology, 2016, 80, 791-791.	5.3	1
64	Where there is inflammation, treatment may reduce disability progression â€“ No. Multiple Sclerosis Journal, 2018, 24, 1810-1812.	3.0	1
65	Unusual neurologic presentation of aseptic abscesses syndrome. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, e469.	6.0	1
66	MRI findings in blinded trials should be available to treating physicians â€“ Yes. Multiple Sclerosis Journal, 2021, 27, 812-813.	3.0	1
67	Longâ€term effect of firstâ€line injectable multiple sclerosis treatments: Input of a timeâ€dependent propensity score. Pharmacoepidemiology and Drug Safety, 2020, 29, 1680-1688.	1.9	0
68	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS: Response to the editor. Multiple Sclerosis Journal, 2020, 26, 1610-1611.	3.0	0